Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1910 studies found for:    "Ovarian Neoplasms"
Show Display Options
Rank Status Study
21 Withdrawn Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Gadofosveset trisodium (Ablavar™ );   Device: MRI
22 Completed TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
Condition: Ovarian Neoplasms
Intervention: Drug: TLK286
23 Completed Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
Condition: Ovarian Neoplasms
Intervention: Drug: docetaxel and cisplatin
24 Completed
Has Results
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Topotecan;   Drug: Pegylated liposomal doxorubicin (PLD);   Drug: BI 6727
25 Terminated Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer
Condition: Ovarian Neoplasms
Intervention: Genetic: EGEN-001 (phIL-12-005/PPC)
26 Recruiting The SOCQER-2 Study Surgery in Ovarian Cancer - Quality of Life Evaluation Research
Condition: Ovarian Neoplasms
Intervention: Other: Observational cohort
27 Terminated Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: SGN-15 (cBR96-Doxorubicin Immunoconjugate);   Drug: Gemzar (Gemcitabine)
28 Completed Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Docetaxel;   Drug: Carboplatin
29 Completed TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: TLK286 HCl for injection;   Drug: topotecan hydrochloride for injection;   Drug: doxorubicin HCl liposome injection
30 Unknown  Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer-Prospective, Randomized Phase II Clinical Trial
Condition: Ovarian Neoplasms
Intervention: Procedure: neoadjuvant chemotherapy (Carboplatin/Docetaxel)
31 Active, not recruiting Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
Condition: Ovarian Neoplasms
Intervention: Biological: pembrolizumab
32 Completed A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients
Condition: Ovarian Neoplasms
Intervention: Drug: taxol
33 Completed
Has Results
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Condition: Ovarian Neoplasms
Intervention: Biological: AMG 479
34 Completed Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer
Condition: Ovarian Neoplasms
Intervention: Genetic: EGEN-001 (phIL-12-005/PPC)
35 Completed TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: TLK286 in Combination with Carboplatin;   Drug: Doxorubicin HCl Liposome Injection
36 Completed
Has Results
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: BIBF1120;   Drug: Placebo
37 Terminated Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Telcyta;   Drug: Liposomal Doxorubicin
38 Completed
Has Results
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Biological: Olaratumab;   Drug: liposomal doxorubicin
39 Terminated
Has Results
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
Condition: Ovarian Neoplasms
Interventions: Drug: BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min;   Drug: BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min;   Drug: BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
40 Completed A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin
Condition: Ovarian Neoplasms
Intervention: Drug: 9-aminocamptothecin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.